| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/24/2001 | US6264975 Methods of hydrating mucosal surfaces |
| 07/24/2001 | US6264973 Apparatus and method for anesthetizing the cervical region of a female |
| 07/24/2001 | US6264966 Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
| 07/24/2001 | US6264962 Use of cinnamic acid or of at least one of its derivatives in a cosmetic composition |
| 07/24/2001 | US6264960 Administering fibric acid compound |
| 07/24/2001 | US6264953 Method of preparation and use for zona pellucida antigens and antibodies for sterilization and contraception |
| 07/24/2001 | US6264938 Administering polydiallylamine and hydroxy-3-methylglutaryl/3-/, coenzyme a reductase |
| 07/24/2001 | US6264937 Mixture with lipase inhibitor |
| 07/24/2001 | US6264935 Hypotensive agent for eyes |
| 07/24/2001 | US6264928 Use of shogaols and gingerols for preparing deodorant compositions |
| 07/24/2001 | US6264923 Antiinflammatory steroid |
| 07/24/2001 | US6264922 Liquid drops containing mixture of liquid, crystal therapeutic agent and surfactant |
| 07/24/2001 | US6264920 Tunable indocyanine dyes for biomedical applications |
| 07/24/2001 | US6264919 Restoring fluorescence; adding biocompatible solvent |
| 07/24/2001 | US6264917 Targeted ultrasound contrast agents |
| 07/24/2001 | CA2331847A1 Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors |
| 07/24/2001 | CA2285266C Extended release formulations of erythromycin derivatives |
| 07/24/2001 | CA2261732C Preparation of crystal form ii of clarithromycin |
| 07/24/2001 | CA2240594C 2,7-substituted octahydro-pyrrolo¬1,2-a|pyrazine derivatives |
| 07/24/2001 | CA2229560C Aliphatic amide feed supplement for ruminants |
| 07/24/2001 | CA2221753C Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 07/24/2001 | CA2220703C Pharmaceutical compositions for the treatment of alcohol addiction |
| 07/24/2001 | CA2218503C Arylsulfonyl hydroxamic acid derivatives |
| 07/24/2001 | CA2201959C Photostable sunscreen composition comprising a dibenzoylmethane derivative and a polysaccharide alkylether and its uses |
| 07/24/2001 | CA2193454C Bioadhesive pharmaceutical composition for the controlled release of active ingredients |
| 07/24/2001 | CA2191844C Acylated enol derivatives as prodrugs of elastase inhibitors |
| 07/24/2001 | CA2177774C Novel piperazine, piperidine and 1,2,5,6-tetrahydropyridine compounds; process_for preparing the same and pharmaceutical compositions containing them |
| 07/24/2001 | CA2174033C Novel pyridine compounds; process for preparing the same and pharmaceutical compositions containing them |
| 07/24/2001 | CA2171972C Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
| 07/24/2001 | CA2111974C Carbapenem derivatives |
| 07/24/2001 | CA2097497C Control of parasitic nematodes |
| 07/24/2001 | CA2092652C Antiherpes peptide derivatives having a ureido n-terminus |
| 07/24/2001 | CA2085465C Thrombin inhibitors based on the amino acid sequence of hirudin |
| 07/24/2001 | CA2066191C Tricyclic ¬6,5,5|/¬6,6,5|-fused oxazolidinone antibacterial agents |
| 07/24/2001 | CA2049822C Stable aqueous preparation |
| 07/24/2001 | CA2047154C Hair dye composition and its application method |
| 07/24/2001 | CA2042112C N'-alkyl-spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors |
| 07/24/2001 | CA2031588C Substituted cyclohexanols and cyclohexylamines as central nervous system agents |
| 07/24/2001 | CA2030773C Stabilized solutions of psychotropic agents |
| 07/24/2001 | CA2030162C Benzothiazepines |
| 07/24/2001 | CA2027936C Cyclic anti-aggregatory peptides |
| 07/24/2001 | CA2026540C Water soluble derivatives of glycoside bioflavonoids, processes for their preparation and related pharmaceutical compositions |
| 07/24/2001 | CA2019369C Sulfur-containing fused pyrimidine derivatives, their production and use |
| 07/19/2001 | WO2001051638A2 Drug metabolizing enzymes |
| 07/19/2001 | WO2001051635A2 Novel stra6 polypeptides |
| 07/19/2001 | WO2001051633A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 07/19/2001 | WO2001051615A1 Method for increasing survival rate of cells in animal cell culture under hypoxia condition |
| 07/19/2001 | WO2001051614A1 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition |
| 07/19/2001 | WO2001051613A1 Method for inhibiting apoptosis under ischemic condition |
| 07/19/2001 | WO2001051603A2 Pharmaceutical composition and method of using the same |
| 07/19/2001 | WO2001051525A1 Heparin with average molecular mass |
| 07/19/2001 | WO2001051524A1 Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects |
| 07/19/2001 | WO2001051515A2 Genes differentially expressed in breast cancer |
| 07/19/2001 | WO2001051499A1 METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES |
| 07/19/2001 | WO2001051497A1 Novel bisphosphonates and uses thereof |
| 07/19/2001 | WO2001051494A1 Inhibitors of prenyl-protein transferase |
| 07/19/2001 | WO2001051493A1 Benzosulfones with calcium antagonist activity |
| 07/19/2001 | WO2001051492A1 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 07/19/2001 | WO2001051491A1 Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof |
| 07/19/2001 | WO2001051489A2 Methods for lowering uric acid levels |
| 07/19/2001 | WO2001051487A1 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| 07/19/2001 | WO2001051485A1 Arylsulfonic acid salts of pyrimidine-based antiviral agents |
| 07/19/2001 | WO2001051482A1 Extraction of flavonoids |
| 07/19/2001 | WO2001051480A1 Agents correcting gene expression regulatory error |
| 07/19/2001 | WO2001051479A2 Tricyclic compounds with antiviral activity |
| 07/19/2001 | WO2001051478A1 Method for the preparation of citalopram |
| 07/19/2001 | WO2001051474A2 Polypharmacophoric agents |
| 07/19/2001 | WO2001051473A1 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 07/19/2001 | WO2001051472A1 New imidazole derivatives |
| 07/19/2001 | WO2001051471A1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments |
| 07/19/2001 | WO2001051470A1 Phenanthridine-n-oxides |
| 07/19/2001 | WO2001051469A1 Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists |
| 07/19/2001 | WO2001051467A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | WO2001051466A1 Indole derivatives as mcp-1 receptor antagonists |
| 07/19/2001 | WO2001051464A1 Novel vitamin d analogues |
| 07/19/2001 | WO2001051463A1 Glyburide composition |
| 07/19/2001 | WO2001051462A1 INHIBITORS OF THE ICE/Ced-3 FAMILY OF CYSTEINE PROTEASES |
| 07/19/2001 | WO2001051456A2 Antibacterial agents |
| 07/19/2001 | WO2001051454A1 Compounds and compositions for delivering active agents |
| 07/19/2001 | WO2001051453A1 Racemic and optically pure metabolites of sibutramine, their preparation, compositions comprising them and their use as dopamine reuptake inhibitors |
| 07/19/2001 | WO2001051089A1 Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
| 07/19/2001 | WO2001051088A1 Composition for reducing plasma triglycerides, platelet aggregation, and oxidative capacity |
| 07/19/2001 | WO2001051085A1 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease |
| 07/19/2001 | WO2001051083A2 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 07/19/2001 | WO2001051079A1 Antigen-specific ige antibody production inhibitors |
| 07/19/2001 | WO2001051078A1 Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
| 07/19/2001 | WO2001051073A2 The parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
| 07/19/2001 | WO2001051068A1 Method and device for increasing and/or decreasing the concentration of immunomodulatory-active substances in substance mixtures |
| 07/19/2001 | WO2001051065A1 Perfusion liquid preparations for ophthalmic operations |
| 07/19/2001 | WO2001051063A1 Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same |
| 07/19/2001 | WO2001051062A1 Compositions for enhancing the immune response |
| 07/19/2001 | WO2001051061A1 Derivatives of polyene macrolides and preparation and use thereof |
| 07/19/2001 | WO2001051060A1 Prevention and treatment of endotoxemia and related complications associated with surgery |
| 07/19/2001 | WO2001051059A1 Processes for preparing clarithromycin polymorphs |
| 07/19/2001 | WO2001051058A1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
| 07/19/2001 | WO2001051057A2 Glycosides and orthoester glycosides of glucocorticoids and uses thereof |
| 07/19/2001 | WO2001051055A2 Pharmaceutical compositions containing steroidal structures and uses thereof |
| 07/19/2001 | WO2001051054A2 Use of cyclopentenone derivatives for bone and periodontal regeneration |
| 07/19/2001 | WO2001051053A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 07/19/2001 | WO2001051052A1 Pharmaceutical preparation containing specific pde v inhibitors |